المؤلفون: Ribeiro, Reitan¹ (AUTHOR) reitanribeiro@hotmail.com, Anselmi, Maria Cristina² (AUTHOR), Schneider, Gunther Alex³ (AUTHOR), Rodrigues Furtado, José Pio⁴ (AUTHOR), Mohamed Abau Shwareb, Mohamed Gaber³ (AUTHOR), Linhares, José Clemente¹ (AUTHOR)

المصدر: Fertility & Sterility. Jul2023, Vol. 120 Issue 1, p188-193. 6p.

مصطلحات موضوعية: *PREMATURE labor, *CHILDBIRTH, *CESAREAN section, *CANCER hospitals, *APGAR score, *LIPOSARCOMA

الملخص (بالإنجليزية): To our knowledge, to report the first case of live birth of a child after uterine transposition (UT), pelvic radiotherapy, and subsequent uterine repositioning. Case report. Tertiary referral cancer hospital. A 28-year-old nulligravid woman with left iliac and thoracic synchronous myxoid low-grade liposarcoma, which was resected with close margins. The patient underwent UT before undergoing pelvic (60 Gy) and thoracic (60 Gy) radiation on October 25, 2018. After radiotherapy, her uterus was reimplanted in the pelvis on February 20, 2019. The patient became pregnant in June 2021 and experienced an uneventful pregnancy until 36 weeks, when the patient started preterm labor and had a cesarean section delivery on January 26, 2022. A boy was delivered after a gestation period of 36 weeks and 2 days (2686 g and 46.5 cm), with Apgar scores of 5 and 9, respectively; both mother and child were discharged the following day. After 1 year of follow-ups, the infant maintained normal development and the patient showed no signs of recurrence. To our knowledge, this case of the first live birth after UT is a proof-of-concept for the viability of UT as a procedure to prevent infertility in patients requiring pelvic radiotherapy. [ABSTRACT FROM AUTHOR]

Abstract (Spanish): Primer nacido vivo tras transposición uterina Hasta donde sabemos, reportar el primer caso de nacido vivo de un niño tras transposición uterina (UT), radioterapia pélvica y posterior reposicionamiento uterino. Caso de estudio. Hospital oncológico terciario de referencia. Mujer de 28 años nuligesta, con liposarcoma mixoide de bajo grado sincrónico torácico e ilíaco izquierdo, que fue extirpado con márgenes estrechos. La paciente fue sometida a UT antes de recibir radioterapia pélvica (60Gy) y torácica (60Gy) el 25 de octubre de 2018. Tras la radioterapia, su útero fue reimplantado en la pelvis el 20 de febrero de 2019. La paciente resultó embarazada en junio de 2021 y experimentó una gestación sin incidentes hasta las 36 semanas, cuando la paciente inició trabajo de parto prematuro y tuvo un parto por cesárea el 26 de enero de 2022. Un niño nació tras de un período de gestación de 36 semanas y 2 días (2686 g y 46,5 cm), con puntuaciones de Apgar de 5 y 9, respectivamente; tanto la madre como el niño fueron dados de alta al día siguiente. Después de 1 año de seguimiento, el bebé mantuvo un desarrollo normal y la paciente no mostró signos de recurrencia. Para nuestro conocimiento. Este primer caso de recién nacido vivo tras UT es una prueba de concepto para la viabilidad del UTcomo procedimiento para prevenir la infertilidad en pacientes que requieran radioterapia pélvica. [ABSTRACT FROM AUTHOR]

المؤلفون: Quinn, M.¹, Huddleston, H.¹, Rosen, M.¹, Cedars, M.¹, Fujimoto, V.Y.¹

المصدر: Fertility & Sterility. Sep2017 Supplement, Vol. 108, pe40-e41. 1p.

مصطلحات موضوعية: *PREMATURE labor, *HUMAN reproductive technology, *CHILDBIRTH, *HUMAN in vitro fertilization, *PREGNANCY complications, *GESTATIONAL age, *LOW birth weight

المؤلفون: Mendola, P.¹, Wallace, M.¹, Hwang, B.S.¹, Liu, D.¹, Grantz, K.¹

المصدر: Fertility & Sterility. Sep2014, Vol. 102 Issue S, pe91-e91. 1p.

مصطلحات موضوعية: *PREMATURE labor, *PREGNANCY complications, *PHYSIOLOGICAL effects of air pollution, *CHILDBIRTH, *CHILDREN'S health

المؤلفون: Sekhon, Lucky^1,2 (AUTHOR) lsekhon@rmany.com, Feuerstein, Jessica¹ (AUTHOR), Pan, Stephanie² (AUTHOR), Overbey, Jessica² (AUTHOR), Lee, Joseph A.¹ (AUTHOR), Briton-Jones, Christine¹ (AUTHOR), Flisser, Eric^1,2 (AUTHOR), Stein, Daniel E.^1,3 (AUTHOR), Mukherjee, Tanmoy^1,2 (AUTHOR), Grunfeld, Lawrence^1,2 (AUTHOR), Sandler, Benjamin^1,2 (AUTHOR), Copperman, Alan B.^1,2 (AUTHOR)

المصدر: Fertility & Sterility. Jun2019, Vol. 111 Issue 6, p1177-1177. 1p.

مصطلحات موضوعية: *FERTILIZATION in vitro, *CHILDBIRTH, *PREMATURE labor, *BLASTOCYST, *LOW birth weight, *INFERTILITY treatment, *BIRTH rate, *CRYOPRESERVATION of organs, tissues, etc., *DRUG administration, *EMBRYO transfer, *ENDOMETRIUM, *ESTRADIOL, *INFERTILITY, *EVALUATION of medical care, *PREGNANCY, *PREGNANCY complications, *TIME, *FETAL development, *TREATMENT effectiveness, *RETROSPECTIVE studies, *FERTILITY drugs

الملخص (بالإنجليزية): Objective: To investigate whether the duration of estrogen administration before euploid embryo transfer affects clinical outcome.Design: Retrospective cohort study.Setting: Private, academic fertility center.Patient(s): Patients (n = 1,439) undergoing autologous freeze-only in vitro fertilization with preimplantation genetic testing (PGT) followed by endometrial preparation with estrogen and progesterone in a frozen, euploid blastocyst transfer cycle.Intervention(s): None.Main Outcome Measure(s): Primary outcome was live birth, and secondary outcomes included implantation, clinical pregnancy, early pregnancy loss, live birth, infant birthweight, low birth weight, infant gestational age at delivery, and preterm birth.Result(s): The duration of estrogen administration (mean: 17.5 ± 2.9 days; range: 10-36 days) before frozen embryo transfer did not impact implantation (odds ratio [OR] 0.99; 95% confidence interval [CI], 0.95-1.03), clinical pregnancy (OR 0.98; 95% CI, 0.94-1.01), early pregnancy loss (OR 1.03; 95% CI, 0.95-1.12), or live birth (OR 0.99; 95% CI, 0.95-1.03). The duration of estrogen exposure did not affect infant birthweight (in grams) (β= -10.65 ± 8.91) or the odds of low birth weight (OR 0.87; 95% CI, 0.68-1.13). For every additional day of estrogen administration, we observed a reduction in gestational age at delivery (in weeks) (β= -0.07 ± 0.03), but the odds of preterm delivery were not affected (OR 1.05; 95% CI, 0.95-1.17).Conclusion(s): Variation in the duration of estradiol supplementation before progesterone initiation does not impact frozen, euploid blastocyst transfer outcome. The duration of estrogen administration was inversely correlated with gestational age at delivery, but this did not translate into an increase in preterm delivery. Further studies are required on the downstream effects of endometrial preparation on the placental-endometrium interface. [ABSTRACT FROM AUTHOR]

Abstract (Spanish): Preparación endometrial antes de transferencia única de blastocistos euploides vitrificados: ¿la duración del tratamiento con estradiol influye en el resultado clínico? Investigar si la duración de la administración de estrógenos antes de la transferencia de un embrión euploide afecta el resultado clínico. Estudio de cohorte retrospectivo. Privado, centro de fertilidad universitario. Pacientes (n=1,439) sometiéndose a fecundación in vitro autóloga para congelación con test genético preimplantacional (PGT) seguido de preparación endometrial con estrógeno y progesterona en un ciclo de transferencia de blastocisto euploide criopresevado. Ninguna. El resultado principal fue nacido vivo, y los resultados secundarios incluyeron implantación, embarazo clínico, pérdida precoz de embarazo, nacido vivo, peso infantil al nacer, bajo peso al nacer, edad gestacional infantil al parto, y parto pretérmino. La duración de la administración de estrógenos (media: 17.5 ± 2.9 días; rango: 10-36 días) antes de transferencia de embriones criopreservados no impactó en la implantación (odds ratio [OR] 0.99; intervalo de confianza 95% [IC], 0.95-1.03), embarazo clínico (OR 0.98; IC 95%, 0.94-1.01), pérdida precoz de embarazo (OR 1.03; IC 95%, 0.95-1.12), o nacido vivo (OR 0.9; IC 95% 0.95-1.03). La duración de la exposición a estrógeno no afectó el peso infantil al nacer (en gramos) (β= -10.65 ± 8.91) o la posibilidad de bajo peso al nacer (OR 0.87; IC 95%, 0.68-1.13). Por cada día adicional de administración de estrógeno, observamos una disminución en la edad gestacional al parto (en semanas) (β= -0.07 ± 0.03), pero la posibilidad de parto pretérmino no fue afectada (OR 1.05; IC 95%, 0.95-1.17). La variación en la duración de la suplementación de estradiol antes del inicio de progesterona no impacta en el resultado de transferencia de blastocisto euploide criopreservado. La duración de la administración de estrógeno se correlacionó inversamente con la edad gestacional al parto, pero esto no se trasladó en un aumento en parto pretérmino. Se requieren estudios adicionales sobre los efectos posteriores de la preparación endometrial sobre la interface placentaria-endometrial. [ABSTRACT FROM AUTHOR]

المؤلفون: Kasman, Alex M.¹ (AUTHOR) akasman@stanford.edu, Zhang, Chiyuan A.¹ (AUTHOR), Li, Shufeng¹ (AUTHOR), Stevenson, David K.² (AUTHOR), Shaw, Gary M.² (AUTHOR), Eisenberg, Michael L.^1,3 (AUTHOR)

المصدر: Fertility & Sterility. May2020, Vol. 113 Issue 5, p947-954. 8p.

مصطلحات موضوعية: *ECLAMPSIA, *PERIPARTUM cardiomyopathy, *PREMATURE labor, *CHILDBIRTH, *GESTATIONAL diabetes, *LOW birth weight, *INTENSIVE care units, *LENGTH of stay in hospitals, *DATABASES, *PREMATURE infants, *NEONATAL intensive care, *TIME, *HEALTH status indicators, *FATHERS, *GESTATIONAL age, *DISEASE incidence, *RETROSPECTIVE studies, *NEONATAL intensive care units, *RISK assessment, *PREGNANCY complications, *BIRTH weight, *COMORBIDITY

مصطلحات جغرافية: UNITED States

الشركة/الكيان: INTERNATIONAL Business Machines Corp. 001368083 IBM

الملخص (بالإنجليزية): Objective: To assess whether paternal health is associated with maternal peripartum and neonatal outcomes.Design: Retrospective cohort study.Setting: University research departments.Patient(s): Analytic sample of children born to paired fathers and mothers covering live births within the United States between 2009-2016.Intervention(s): Paternal health status (e.g., metabolic syndrome diagnoses, individual chronic disease diagnoses).Main Outcome Measure(s): Primary outcome of preterm birth (i.e., live birth before 37 weeks), and secondary outcomes of low birth weight, neonatal intensive care unit (NICU) stay, gestational diabetes, preeclampsia, eclampsia, and length of maternal stay.Result(s): The IBM Marketscan Research database covers reimbursed health care claims data on inpatient and outpatient encounters who are privately insured through employment-sponsored health insurance. We assessed 785,809 singleton live births, with 6.6% born preterm. The presence of paternal comorbidities was associated with higher odds of preterm birth, low birth weight (LBW), and NICU stay. After adjusting for maternal factors, fathers with most or all components of the metabolic syndrome had 19% higher odds of having a child born preterm (95% CI 1.11-1.28), 23% higher odds of LBW (95% CI 1.01-1.51), and 28% higher odds of NICU stay (95% CI 1.08-1.52). Maternal morbidity (e.g., gestational diabetes or preeclampsia) was also positively associated with preconception paternal health.Conclusion(s): Increased preconception paternal comorbidity may be associated with negative infant and maternal outcomes. Although the paternal effect remains modest, these findings highlight the importance of the health of both parents, particularly the mother, on healthy pregnancy. [ABSTRACT FROM AUTHOR]

Abstract (Spanish): Asociación entre la salud preconcepcional del varón sobre los resultados perinatales: estudio de datos de solicitudes de reembolso en EE.UU Evaluar si la salud del varón está asociada con los resultados maternos periparto y neonatales. Estudio de cohorte retrospectiva. Departamentos de investigación universitarios. Muestra analítica de hijos nacidos de padres y madres emparejados que cubre los nacimientos en Estados Unidos entre 2009 y 2016. Estado de salud de los progenitores (e.g. diagnóstico de síndrome metabólico, diagnósticos de enfermedades crónicas individuales). Resultado primario: nacimiento pretérmino (i.e. nacido vivo antes de la semana 37) y resultados secundarios: bajo peso, estancia en unidad de cuidados intensivos neonatales (NICU), diabetes gestacional, preeclampsia, eclampsia y duración de la estancia materna. La base de datos IBM Marketscan Research abarca los datos de las solicitudes de reembolso de actos médicos en pacientes ingresados y ambulatorios con seguro médico privado pagado por el empleador. Evaluamos 785.809 partos únicos con recién nacido vivo, con 6,6% nacidos pretérmino. La presencia de comorbilidades paternas se asoció con una mayor probabilidad de parto pretérmino, bajo peso al nacer (LBW) y estancia en NICU. Tras ajustar por factores maternos, los padres con la mayoría o todos los componentes del síndrome metabólico tuvieron un riesgo un 19% mayor de tener un hijo pretérmino (IC 95% 1.11—1.28), un riesgo un 23% mayor de LBW (IC 95% 1.01—1.51) y un riesgo un 28% mayor de estancia en NICU (IC 95% 1.08—1.52). La morbilidad materna (e.g., diabetes gestacional o preeclampsia) también estuvo asociada positivamente con la salud paterna preconcepcional. El aumento de comorbilidades preconcepcionales en el varón puede estar asociado con resultados negativos maternos y en neonatos. Aunque el efecto paterno es modesto, estos resultados resaltan la importancia de la salud de ambos progenitores, sobre todo la madre, para un embarazo saludable. [ABSTRACT FROM AUTHOR]

المؤلفون: Dovey, Serena¹ serena.dovey@gmail.com, McIntyre, Kerri², Jacobson, Debbie³, Catov, Janet¹, Wakim, Anthony¹

المصدر: Fertility & Sterility. Sep2011, Vol. 96 Issue 3, p585-589. 5p.

مصطلحات موضوعية: *LUTEINIZING hormone, *PROGESTERONE, *HUMAN in vitro fertilization, *PREMATURE labor, *HEALTH outcome assessment, *CHILDBIRTH, *RETROSPECTIVE studies, *GONADOTROPIN releasing hormone

مستخلص: Objective: To determine whether a premature rise in the level of luteinizing hormone (LH) without a concomitant increase in the level of progesterone is detrimental to pregnancy outcome in flexible gonadotropin-releasing hormone (GnRH) antagonist in vitro fertilization (IVF) cycles. Design: Retrospective cohort study. Setting: Large academic IVF practice. Patient(s): All women undergoing their first GnRH-antagonist in vitro fertilization cycle at the University of Pittsburgh Medical Center between January 1, 2007, and October 1, 2010. Intervention(s): None. Main Outcome Measure(s): Primary outcome measures included the overall pregnancy rate, live-birth/ongoing pregnancy rate, and early pregnancy loss compared between cycles with and without a premature rise in the LH level; secondary outcome measures included the number of oocytes retrieved and embryos obtained during the cycle. Result(s): Overall, 451cycles were included in the analysis. Patients who experienced a premature rise in LH had improved ovarian reserve parameters and had more oocytes retrieved compared with patients who did not experience an LH rise. However, the premature rise in LH was associated with a decreased ongoing pregnancy rate despite these improvements in cycle parameters. Conclusion(s): The incidence of premature LH rise without a concomitant progesterone increase is more common than previously reported and is associated with decreased rates of ongoing pregnancy. [Copyright &y& Elsevier]

المؤلفون: Vitale, Salvatore Giovanni¹ (AUTHOR), Riemma, Gaetano² (AUTHOR), Cianci, Antonio¹ (AUTHOR)

المصدر: Fertility & Sterility. Feb2020, Vol. 113 Issue 2, p335-336. 2p.

مصطلحات موضوعية: *ANTI-Mullerian hormone, *PATHOLOGY, *CHILDBIRTH, *PREMATURE labor, *SEX hormones, *INFERTILITY, *INDUCED ovulation, *DURATION of pregnancy, *POLYCYSTIC ovary syndrome

المؤلفون: He, Hui¹ (AUTHOR), Jing, Shuang¹ (AUTHOR), Lu, Chang Fu^1,2,3 (AUTHOR), Tan, Yue Qiu^1,2,3 (AUTHOR), Luo, Ke Li^1,3 (AUTHOR), Zhang, Shuo Ping^1,3 (AUTHOR), Gong, Fei^1,3 (AUTHOR), Lu, Guang Xiu^1,2,3 (AUTHOR), Lin, Ge^1,2,3 (AUTHOR) linggf@hotmail.com

المصدر: Fertility & Sterility. Jul2019, Vol. 112 Issue 1, p82-88. 7p.

مصطلحات موضوعية: *CHILDBIRTH, *FETAL macrosomia, *GENETIC testing, *INTRACYTOPLASMIC sperm injection, *FERTILIZATION in vitro, *PREMATURE labor, *BIOPSY, *BIRTH weight, *LOW birth weight, *BLASTOCYST, *COMPARATIVE studies, *EMBRYO transfer, *GESTATIONAL age, *PREMATURE infants, *RESEARCH methodology, *EVALUATION of medical care, *MEDICAL cooperation, *PREGNANCY, *PREIMPLANTATION genetic diagnosis, *RESEARCH, *RISK assessment, *FLUORESCENCE in situ hybridization, *EVALUATION research, *TREATMENT effectiveness, *PREDICTIVE tests, *RETROSPECTIVE studies

الملخص (بالإنجليزية): Objective: To investigate whether blastocyst biopsy in preimplantation genetic testing (PGT) increases the risk of adverse neonatal outcomes.Design: Retrospective cohort study.Setting: University-affiliated center.Patients: Live births after blastocyst biopsy combined with frozen ET (PGT group) and frozen blastocyst transfer after in vitro fertilization or intracytoplasmic sperm injection (control group).Intervention(s): Blastocyst biopsy.Main Outcome Measure(s): Gestational age (GA), birth weight (BW), and rates of preterm birth (PB), very preterm birth (VPB), extreme preterm birth (EPB), low birth weight (LBW), very low birth weight (VLBW), and macrosomia.Result(s): No significant differences were observed in the sex ratio, GA, PB, VPB, EPB, BW, or rates of LBW, VLBW, and macrosomia between the PGT and control groups for either singletons or twins. However, the cesarean section rate of the PGT group was significantly higher than that of the control group for twins (adjusted odds ratio, 2.383 [1.079, 5.259]). Regarding fluorescence in situ hybridization-PGT neonates, neonatal outcomes, including GA, BW, and rates of PB, VPB, LBW, and VLBW, did not differ between the different groups of biopsied cells (≥10 group and <10 group) for either the grade B or grade C trophectoderm score subgroups; however, in the grade B trophectoderm score subgroup, the rate of boy babies in the ≥10 group was significantly higher than that in the <10 group (83.3% vs. 40.9%). The association between the number of biopsied cells and GA/BW was not statistically significant.Conclusion(s): Blastocyst biopsy may not add additional risk to neonatal outcomes when compared with a control group. [ABSTRACT FROM AUTHOR]

Abstract (Spanish): Desenlace neonatal de recién nacidos vivos tras biopsia de blastocisto en ciclos de diagnóstico genético preimplantacional: seguimiento de 1721 niños Investigar si la biopsia de blastocisto en diagnóstico genético preimplantacional (PGT) aumenta el riesgo de desenlaces neonatales adversos. Estudio retrospectivo de cohortes. Centro universitario. recién nacidos vivos después de biopsia de blastocisto con transfer de embriones congelados (grupo PGT) y después de transfer de blastocisto congelado tras fecundación in-vitro o inyección espermática intracitoplásmica (grupo control). biopsia de blastocisto. Edad gestacional (GA), peso al nacer (BW) y tasas de prematuridad (PB), prematuridad severa (VPB), prematuridad extrema (EPB), bajo peso al nacer (LBW), muy bajo peso al nacer (VLBW) y macrosomia. No se observaron diferencias significativas en proporción de sexos, GA, PB, VPB, EPB, ni en tasas de LBW, VLBW, ni macrosomia entre los grupos PGT y control en embarazos únicos ni en gemelares. Sin embargo, la tasa de cesárea del grupo PGT fue significativamente mayor que del grupo control en embarazos gemelares (razón de momios ajustada, 2.383 [1.079, 5.259]). En cuanto a los neonatos nacidos tras PGT por hibridación fluorescente in-situ, los desenlaces neonatales, incluidos GA, BW, y tasas de PB, VPB, LBW y VLBW, no difirieron entre los grupos según el número de células biopsiadas (grupo > 10 y grupo <10) en los subgrupos de trofectodermo de grado B o grado C. Sin embargo, en el subgrupo de trofectodermo de grado B, la tasa de bebés varones en el grupo de > 10 fue significativamente mayor que la del grupo <10 (83.3% vs. 40.9%). La asociación entre el número de células biopsiadas y GA/BW no fue estadísticamente significativa. La biopsia de blastocisto podría no añadir riesgo adicional al desenlace neonatal comparada con el grupo control. [ABSTRACT FROM AUTHOR]

المؤلفون: Zhang, Wendy Y.¹ (AUTHOR) wendyz@stanford.edu, von Versen-Höynck, Frauke^1,2 (AUTHOR), Kapphahn, Kristopher I.³ (AUTHOR), Fleischmann, Raquel R.¹ (AUTHOR), Zhao, Qianying¹ (AUTHOR), Baker, Valerie L.⁴ (AUTHOR)

المصدر: Fertility & Sterility. Aug2019, Vol. 112 Issue 2, p283-283. 1p.

مصطلحات موضوعية: *PREECLAMPSIA, *PREMATURE rupture of fetal membranes, *CHILDBIRTH, *BIRTH weight, *PREMATURE labor, *INTENSIVE care units, *HOSPITAL admission & discharge, *GESTATIONAL diabetes

الملخص (بالإنجليزية): Objective: To assess whether pregnancies achieved with trophectoderm biopsy for preimplantation genetic testing (PGT) have different risks of adverse obstetric and neonatal outcomes compared with pregnancies achieved with IVF without biopsy.Design: Observational cohort.Setting: University-affiliated fertility center.Patient(s): Pregnancies achieved via IVF with PGT (n = 177) and IVF without PGT (n = 180) that resulted in a live birth.Intervention(s): None.Main Outcome Measure(s): Maternal outcomes including preeclampsia and placenta previa and neonatal outcomes including birth weight and birth defects.Result(s): There was a statistically significant increase in the risk of preeclampsia among IVF+PGT pregnancies compared with IVF without PGT pregnancies, with an incidence of 10.5% versus 4.1% (adjusted odds ratio [aOR] = 3.02; 95% confidence interval [95% CI], 1.10, 8.29). The incidence of placenta previa was 5.8% in IVF+PGT pregnancies versus 1.4% in IVF without PGT pregnancies (aOR = 4.56; 95% CI, 0.93, 22.44). Similar incidences of gestational diabetes, preterm premature rupture of membranes, and postpartum hemorrhage were observed. IVF+PGT and IVF without PGT neonates did not have a significantly different gestational age at delivery or rate of preterm birth, low birth weight, neonatal intensive care unit admission, neonatal morbidities, or birth defects. All trends, including the significantly increased risk of preeclampsia in IVF+PGT pregnancies, persisted upon stratification of analysis to only singleton live births.Conclusion(s): To date, this is the largest and most extensively controlled study examining maternal and neonatal outcomes after trophectoderm biopsy. There was a statistically significant three-fold increase in the odds of preeclampsia associated with trophectoderm biopsy. Given the rise in PGT use, further investigation is warranted. [ABSTRACT FROM AUTHOR]

Abstract (Spanish): Resultados maternos y neonatales asociados con biopsia de trofectodermo Evaluar si los embarazos logrados con la biopsia de trofoectodermo para pruebas genéticas preimplantacionales (PGT) tienen diferentes riesgos de resultados adversos obstétricos y neonatales en comparación con los embarazos logrados con la FIV sin biopsia. Cohorte observacional. Centro de fertilidad afiliado a la universidad. Embarazos logrados a través de fecundación in vitro (FIV) con PGT (n = 177) y FIV sin PGT (n = 180) que resultaron en un nacido vivo. Ninguna. Resultados maternos que incluyen preeclampsia y placenta previa y resultados neonatales que incluyen el peso y defectos de nacimiento. Hubo un aumento estadísticamente significativo en el riesgo de preeclampsia entre los embarazos de FIV+PGT en comparación con los embarazos de FIV sin PGT, con una incidencia de 10,5% versus 4,1% (odds ratio ajustado [aOR] = 3,02; intervalo de confianza del 95% [95% CI], 1,10, 8,29). La incidencia de placenta previa fue del 5,8% en los embarazos con FIV+PGT versus 1,4% en los embarazos con FIV sin PGT (aOR = 4,56; 95% CI, 0,93, 22,44). Incidencias similares de diabetes gestacional, rotura prematura de membranas prematuras y hemorragia posparto fueron observados. La FIV con PGT y la FIV sin PGT no tuvieron una edad gestacional significativamente diferente en el momento del parto o la tasa del nacimiento prematuro, bajo peso al nacer, ingreso a la unidad de cuidados intensivos neonatales, morbilidad neonatal o defectos de nacimiento. Todas las tendencias, incluyendo el aumento significativo del riesgo de preeclampsia en los embarazos de FIVPGT persistió tras la estratificación del análisis solo para recién nacidos únicos. Hasta la fecha, este es el estudio más grande y más ampliamente controlado que examina los resultados maternos y neonatales después de la biopsia de trofectodermo. Hubo un aumento triple estadísticamente significativo en las probabilidades de preeclampsia asociada con la biopsia de trofectodermo. Dado el aumento en el uso de PGT, se justifica una mayor investigación. [ABSTRACT FROM AUTHOR]

المؤلفون: Ozgur, Kemal¹ kemalozg@yahoo.com, Berkkanoglu, Murat¹, Bulut, Hasan¹, Humaidan, Peter², Coetzee, Kevin¹

المصدر: Fertility & Sterility. Oct2015, Vol. 104 Issue 4, p899-907.e3. 1p.

مصطلحات موضوعية: *BLASTOCYST, *RETROSPECTIVE studies, *REPRODUCTIVE technology, *CHILDBIRTH, *MISCARRIAGE, *GESTATIONAL age, *PREGNANCY, *PREMATURE labor, *BIRTH weight, *BIRTH rate, *CRYOPRESERVATION of organs, tissues, etc., *EMBRYO transfer, *PREMATURE infants, *EVALUATION of medical care

مستخلص: Objective: To investigate the possible effect of controlled ovarian stimulation on the perinatal outcomes of assisted reproductive technology pregnancies, by comparing the outcomes from fresh ET with frozen ET (FET) with blastocysts of similar quality.Design: Retrospective observational study.Setting: Private fertility center.Patient(s): Seven hundred eighty-four fresh transfers and 382 vitrified-warmed double blastocyst transfers.Intervention(s): None.Main Outcome Measure(s): Miscarriage, perinatal mortality, preterm delivery, live birth, live-birth weights, and gestational age of live births.Result(s): FET resulted in higher implantation rates (51.5% vs. 40.6%), higher live-birth rates per transfer (56.8% vs. 44.3%), and lower ectopic pregnancy rates (0.32% vs. 1.80%). FET pregnancies also had higher day 14 βhCG levels per implantation (148.2 vs. 176.2 IU/L) and higher infant birth weights (singletons Δ109.4 g, twins Δ124 g). Female infants benefitted the most in terms of birth weight. Miscarriage, premature delivery, perinatal morbidity, and live birth per pregnancy were all nonsignificantly different between fresh ET and FET.Conclusion(s): Clinically significant differences between the peri-implantation and perinatal outcomes of fresh ET and FET suggest better endometrial receptivity and placentation in FET cycles. [ABSTRACT FROM AUTHOR]